化学
单克隆抗体
对接(动物)
计算生物学
癌症免疫疗法
CTLA-4号机组
免疫疗法
免疫系统
抗体
重组DNA
肽
生物化学
体外
免疫学
生物
细胞毒性T细胞
医学
基因
护理部
作者
S V Podlesnykh,V. V. Lampatov,Alexander F. Khlebnikov,Andrei I. Chapoval
出处
期刊:Biomeditsinskaya khimiya
[Institute of Biomedical Chemistry]
日期:2020-01-01
卷期号:66 (2): 156-161
标识
DOI:10.18097/pbmc20206602156
摘要
Current advances in research of immune checkpoints CTLA-4, PD-1, PD-L1, opened new possibilities for effective cancer immunotherapy using monoclonal antibodies. However, antibodies have a number of limitations for clinical use, which provides a basis for the search for low molecular weight compounds capable of regulating (blocking) molecules that inhibit the immune response. This paper presents the results of molecular docking and evaluation of synthetic peptide interaction with a CTLA-4 molecule. Using mathematical modeling, it was shown that peptides interacted with the 99MYPPPY104 loop of the CTLA-4 protein and could potentially block the interaction of the CTLA-4 receptor with its natural ligand B7-1. The specificity of the interaction between the identified peptide and recombinant chimeric CTLA-4 protein was evaluated. The detected synthetic peptide can be used for the development of immunomodulatory drugs for therapy of cancer or autoimmune diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI